Immunotherapy for Alzheimer disease

mAbs

Volumn 1, Issue 2, 2009, Pages 112-114

  Gouras, Gunnar K ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Alzheimer disease; Amyloid; Immunotherapy; Tau; Vaccine

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BETA AMYLOID VACCINE; FREUND ADJUVANT; TAU PROTEIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALLELE; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN DAMAGE; CHEMICAL MENINGOENCEPHALITIS; CLINICAL TRIAL; COGNITIVE DEFECT; HUMAN; MENINGOENCEPHALITIS; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; T LYMPHOCYTE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; TAU PROTEINS; TREATMENT OUTCOME; VACCINES;

EID: 77953663334     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.2.7829     Document Type: Article

References (20)

1. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-177 (Pubitemid 29327547)
2. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408:979-982 (Pubitemid 32101644)
3. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408:982-985 (Pubitemid 32101645)
4. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6:916-919 (Pubitemid 30644751)
5. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38:547-554 (Pubitemid 36645030)
6. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372:216-223 (Pubitemid 351978111)
7. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192:106-113
8. Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging 2005; 26:1235-1244 (Pubitemid 41338539)
9. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43:321-332 (Pubitemid 39061125)
10. Tampellini D, Magrané J, Takahashi RH, Li F, Lin MT, Almeida CG, et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 2007; 282:18895-18906 (Pubitemid 47100144)
11. Arbel M, Solomon B. Immunotherapy for Alzheimer's disease: attacking amyloid-beta from the inside. Trends Immunol 2007; 28:511-513 (Pubitemid 350101422)
12. Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 2006; 33:270-298 (Pubitemid 43849931)
13. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7:327-340
14. Diamond B, Kowal C, Huerta PT, Aranow C, Mackay M, DeGiorgio LA, et al. Immunity and acquired alterations in cognition and emotion: lessons from SLE. Adv Immunol 2006; 89:289-320.
15. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDAreceptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091-1098
16. Demattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98:8850-8855 (Pubitemid 32678116)
17. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316:750-754 (Pubitemid 46717684)
18. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. Co-occurrence of Alzheimer's disease beta-amyloid and tau pathologies at synapses. Neurobiol Aging 2008; ePub in press.
19. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27:9115-9129 (Pubitemid 47312068)
20. Arbel M, Yacoby I, Solomon B. Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci USA 2005; 102:7718-7723 (Pubitemid 40741037)